CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer
February 1st 2024Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.
Watch
Safety/Efficacy Findings Support Cabozantinib in RAI-Refractory DTC
February 1st 2024Francis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.
Watch
About the CheckMate 901 Trial of Frontline Nivolumab Plus Chemo in mUC
January 30th 2024Michiel S. Van der Heijden, MD, PhD, discusses background of the phase 3 CheckMate 901 study which evaluated concurrent frontline nivolumab and gemcitabine/cisplatin followed by nivolumab maintenance therapy among patients with urothelial carcinoma.
Watch
Management Approaches for HR+/HER2- mBC Based on Metastasis Location and Disease Burden
January 29th 2024Virginia Kaklamani, MD, DSc, details that disease burden and location of metastases in patients with HR+/HER2- metastatic breast cancer guide approaches to management, with visceral metastases indicating potentially faster progression and more concerning symptoms.
Watch
Insights for Oncologists on Follow-Up Data From KEYNOTE-B61 in nccRCC
January 27th 2024Martin H. Voss, MD, discusses what community oncologists should takeaway from the the extended follow-up data of the phase 2 KEYNOTE-B61 study which assessed first-line pembrolizumab plus lenvatinib for patients with non-clear cell renal carcinomas.
Watch